Innatus Therapeutics (Shanghai) Co. Ltd. has synthesized integrin β2 regulators reported to be useful for the treatment of alopecia areata, gouty arthritis, autoimmune hepatitis, inflammatory bowel disease, peritonitis, rheumatoid arthritis, Sjögren’s disease and systemic lupus erythematosus, among others.
Enveda has obtained IND clearance from the FDA and initiated a phase I trial of ENV-6946, a first-in-class oral small molecule for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn’s disease.
Numab Therapeutics AG and Kaken Pharmaceutical Co. Ltd. have entered into a strategic licensing and co-development agreement for NM-81, a multi-specific antibody for the treatment of inflammatory bowel disease (IBD).
Interline Therapeutics Inc. has identified new compounds receptor-interacting serine/threonine-protein kinase 2 (RIPK2; RIP-2) inhibitors reported to be useful for the treatment of inflammatory bowel disease (IBD).
Shenzhen Salubris Pharmaceuticals Co. Ltd. has synthesized compounds acting as MIR124 activators reported to be useful for the treatment of inflammatory bowel disease and inflammatory disorders.
A new study aimed to investigate the therapeutic effect of ISM012-042 in a chronic T-cell transfer-induced colitis model in mice that mimicked Crohn’s disease.
Arcus Biosciences Inc. has announced five new research programs for autoimmune and inflammatory diseases, and is targeting initiation of the first clinical studies next year.
Researchers from Onco3r Therapeutics BV presented preclinical data on O3R-5671, a novel salt-inducible kinase 3 (SIK3) inhibitor developed for the treatment of inflammatory bowel disease and other autoimmune diseases.
